VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients

Abdulraheem Yacoub, MD, The University of Kansas, Westwood, KS, discusses the potential addition of parsaclisib to ruxolitinib for the treatment of patients with myelofibrosis (MF). Dr Yacoub first highlights the promising activity that has been observed with the use of parsaclisib, and then gives an overview of clinical trials investigating this combination. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter